IL6 and cancer: Dysregulation of circulating inflammatory markers and cytokines such as interleukin-1 receptor antagonist (IL-1RA), interleukin-6 (IL-6) and C-reactive protein (CRP) has been reported in cancer patients and survivors experiencing CRF [5–8].